It's a long-awaited day for many advanced melanoma patients in New Zealand
It's a long-awaited day for many advanced melanoma patients in New Zealand
1 June 2025
From today many with stage 3B to stage 4 melanoma will now have wider access to Keytruda and the branded drug Tafinlar and Mekinist.
Melanoma New Zealand Chief executive Andrea Newland says this brings New Zealand further in line with international standards of care.
© 2025 Newstalk ZB, NZCity